Alcon’s operating income grows strongly
Alcon, the eye care division of Novartis, saw its net sales increase to US$2.7 billion in the third quarter ended Sept. 30, up 5 percent in dollars and 6 percent in constant currencies. A positive factor was the approval given by the European Commission to Simbrinza, Alcon's new drug for ...
Already an Eyewear Intelligence subscriber? Sign in here.
Subscribe today
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
- Organisation-wide access across offices, people and devices
To continue reading this article register now.